VRTX 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-04

• and growth from diversification into additional disease areas.

• Our cost of sales as a percentage of our net product revenues increased to 14.7% in the second

• quarter of 2026 as compared to 13.8% in the second quarter of 2025, as a result of changes in

• product mix, partially offset by a lower blended royalty rate for our CF medicines.

• •In the second quarter of 2026, we secured reimbursement for ALYFTREK in four additional countries, including

相对上期删除的文字 · 来源:10-Q · 2026-05-05

• Our cost of sales as a percentage of our net product revenues was 13.2% in each of the first

• quarters of 2026 and 2025, as a result of a lower overall royalty rate for our CF medicines, offset

• •The U.S. Food and Drug Administration (the “FDA”) approved label extensions for ALYFTREK and TRIKAFTA,

• expanding availability of these medicines to approximately 95% of all people with CF in the United States (the

• “U.S.”). With these label extensions, approximately 800 people with CF in the U.S. are newly eligible for a

相对上期新增的文字 · 来源:10-Q · 2026-08-04

• The information presented below supplements the risk factors set forth in Part I, Item 1A. “Risk Factors” of our Annual

• Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 13, 2026.

• We may be unable to complete the Crinetics Acquisition, successfully integrate Crinetics’ business, or realize the

• potential commercial benefits of the strategic acquisition, which could adversely affect our business and financial

• Our inability to complete the Crinetics Acquisition or to successfully integrate the Crinetics business could have a

相对上期新增的文字 · 来源:10-Q · 2026-08-04

• On July 30, 2026, we entered into a revolving credit agreement (the “2026 Revolver”), with Vertex Pharmaceuticals

• (Europe) Limited, a private limited company incorporated in England and Wales and a wholly-owned subsidiary of Vertex,

• as a co-borrower, Vertex Pharmaceuticals (Ireland) Limited, a private company limited by shares incorporated in Ireland and

• a wholly-owned subsidiary of Vertex, as a co-borrower, certain other wholly-owned subsidiaries of Vertex party thereto as

• subsidiary guarantors, the lenders and issuing banks party thereto and Bank of America, N.A., as administrative agent, which